Wells Fargo Begins Coverage of Illumina with Outperform Rating | GenomeWeb

NEW YORK (GenomeWeb News) – Wells Fargo Securities on Monday initiated coverage of Illumina with an Outperform rating, saying the company is "the clear market leader in next-generation sequencing, which we believe will be the primary tool enabling the application of personalized medicine."

The investment bank valued the San Diego-based company's shares in the $90 to $95 range and estimated its EPS for full-year 2013 at $1.72 on revenues of $1.38 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.